Lupin Completes Acquisition of VISUfarma to Expand Ophthalmology Portfolio in Europe

With the integration of VISUfarma, Lupin’s ophthalmology portfolio now includes more than 60 branded products.

Lupin Limited has completed the acquisition of VISUfarma B.V., a European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP. The move is aimed at expanding Lupin’s specialty care portfolio and strengthening its footprint in European markets.

With the integration of VISUfarma, Lupin’s ophthalmology portfolio now includes more than 60 branded products. These span therapeutic areas such as dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals.

VISUfarma brings an established commercial presence across key European markets, including Italy, the United Kingdom, Spain, Germany, and France. The company also contributes a specialized team with experience in ophthalmology, along with established distribution networks and local market knowledge.

The acquisition aligns with increasing global demand for eye care solutions, driven by demographic trends such as an ageing population and the rising prevalence of diabetes-related eye conditions.

Vinita Gupta, CEO of Lupin, said the acquisition adds a differentiated portfolio of ophthalmology products and strengthens the company’s commercial infrastructure in Europe. She noted that the deal is expected to support the expansion of Lupin’s specialty business.

Paolo Cioccetti, CEO Italy at VISUfarma, said the partnership would combine VISUfarma’s ophthalmology focus with Lupin’s global capabilities to support further growth in the segment.

The acquisition marks Lupin’s continued focus on specialty therapeutics, with ophthalmology emerging as a key growth area within its global portfolio.

Stay tuned for more such updates on Digital Health News